TEC方案在晚期乳腺癌新辅助化疗(NCT)中的疗效分析  

Analysis on the efficacy of TEC regimen as neoadjuvant chemotherapy in advanced breast cancer(NCT)

作　　者：刘丽娟[1] 赖雁威 

机构地区：[1]北京大学深圳医院药剂科,广东深圳518036

出　　处：《中国医院药学杂志》2014年第16期1391-1395,共5页Chinese Journal of Hospital Pharmacy

摘　　要：目的:观察多西他赛+环磷酞胺+表柔比星新辅助化疗(neoadjuvant chemotherapy,NCT)方案对原位晚期乳腺癌的有效性。方法:研究对象为58名女性晚期乳癌患者,其中29例(50%)为不能手术的T4期伴炎性癌症。治疗前,肿瘤平均大小为8 cm。32名患者(63%)雌激素受体为阳性,10例(18%)HER2过表达。采用的NCT方案是TEC(多西他赛+环磷酞胺+表柔比星),治疗开始后静滴多西他赛(TAX)75 mg·m-2,环磷酞胺(CTX)500 mg·m-2,静滴,表柔比星(EPI)60 mg·m-2,每隔28 d化疗1次,术前共4个疗程。结果:经新辅助化疗后,所有患者都可进行手术。其中16例患者(28%)达到了乳腺的病理完全缓解(pCR),12例(21%)同时达到乳腺和腋下淋巴结的pCR。所有患者都完成了预定的化疗方案,常见的不良反应包括脱发、贫血等。结论:采用TEC新辅助化疗对于晚期乳腺细胞癌(Locally advanced breast carcinoma,LABC),甚至肿瘤更大且非HER2过表达的患者有良好的效果,且患者耐受性好,值得在临床上推广使用。OBJECTIVE To observe the effects of taxotere ＋ cytoxan ＋ epirubicin in advanced breast cancer as neoadjuvant chemotherapy. METHODS 58 cases of women with advanced breast cancer patients were enrolled into this study. 28 （50%） cases of patients were not suitable for operation （phase T4 or inflammatory cancer）. The average tumor size was 8 cm. 32 patients （63% ） had estrogen receptor positive tumors and 10 patients （18%） had tumors with HER2 overexpression. TEC （taxotere ＋ cytoxan ＋ epirubicin） for NCT was docetaxel 75 mg·m-2, CTX （cyclophosphamide） 500 mgom-2, EPI （epirubicin） 60 mg·m-2, through intravenous, every 28 clays as a course of treatment. They accepted total of 4 chemotherapy before preoperative treatment. RESULTS After neoadjuvant chemotherapy, all patients were operated. Pathology of breast achieved corn plete remission （pCR） in 16 patients （28%） and 12 cases （21%） reached the breast and axillary lymph node pCR. All patients had completed chemotherapy scheduled, the common side effects including hair loss and anemia. CONCLUSION Neoadjuvant chemotherapy with TEC for local advanced breast cancer, even for greater tumor and non HER2 positive patients, has a good effect and well tolerated. TEC regimen could be worthy for clinical use in advanced breast cancer.

关 键 词：新辅助化疗 乳腺癌 多西他赛 

分 类 号：R969[医药卫生—药理学]